The advertisement promotes the medication Entyvio (vedolizumab) as being superior to Humira (adalimumab) for patients with moderately to severely active ulcerative colitis, highlighting its efficacy in clinical remission.
Creative Information
| CID: | b8d3208a-bbde-42b3-8294-f243c4b5938e |
| CRID: | 82_6854-857426 |
| Domain: | entyviohcp.com |
| Seat: | PP |
| Size: | 160x600 |
| Bid: | $2.10 |
| Timestamp: | 11/10/2025, 6:46:45 PM |
| Declared IAB Categories: |
Analysis
5 succeeded(100% complete)
| Task | Status | Last Updated | Duration | Actions |
|---|---|---|---|---|
| ad_analysis | success | 11/10/2025, 8:28:08 PM | 5.93s | |
| adomain_analysis | success | 11/10/2025, 8:44:27 PM | 3.14s | |
| adomain_capture | success | 11/10/2025, 8:44:06 PM | 0.08s | |
| ad_render | success | 11/10/2025, 8:28:02 PM | 25.44s | |
| brand_mapping | success | 11/10/2025, 6:46:46 PM | 0.12s | |
Analysis Results
Ad Format: banner
Brands: Entyvio
Sensitive:Pharmaceutical Products
Quality:Adomain not match landing page domain
| Size: | 160x600 | ||||||||||||||||||||||
| Data Transferred: | 1771.38 KB | ||||||||||||||||||||||
| Render Time: | 9.98 Seconds | ||||||||||||||||||||||
| Creative Inferred IAB Categories: |
| ||||||||||||||||||||||
| Creative Inferred IAB Ad Products: |
| ||||||||||||||||||||||
| Domain Inferred IAB Categories: |
| ||||||||||||||||||||||
| Domain Inferred IAB Ad Products: |
| ||||||||||||||||||||||
| Landing Page: | |||||||||||||||||||||||
| Total Ad Size: | 1771.50 KB | ||||||||||||||||||||||
| Requests Made: |
|
Advertiser Domain

Ad Preview
Landing Page

Creatives

